Navigation Links
KEW Group Launches CancerPlex(SM) Assay to Bring State-of-the-Art Genomic Testing to Community Oncologists

CAMBRIDGE, Mass., Oct. 25, 2013 /PRNewswire/ -- KEW Group Inc. (KEW), a privately held oncology services company located in Cambridge, Mass., announced today the launch of CancerPlexSM, a highly versatile and comprehensive gene testing panel to evaluate genetic changes in a patient's tumor to help oncologists effectively manage treatment options. CancerPlexSM was developed and validated in KEW's CLIA laboratory and can be used for examination of the genetic profile of many common cancers.

KEW Group is also developing state-of-the-art evidence-based therapeutic pathways that provide information about when it is appropriate to conduct diagnostic testing, including molecular diagnostics, and how that information can be used in clinical decision support.

"With the addition of the KEW CancerPlexSM, we are providing an important new service to community oncologists by incorporating state-of-the art genomic testing with evidence-based diagnostic and treatment pathways to benefit cancer patients," said Kathy Behrens Wilsey, CEO of KEW Group Inc.  "These services are expected to provide the basis for both current and next generation cancer treatments."

KEW's CancerPlexSM assay utilizes next-generation sequencing to analyze more than 400 known cancer genes involved in cancer initiation and progression. The resulting information from this tumor mutation analysis can be used by physicians to supplement other patient-specific information and assist in the determination of treatment options.

About KEW Group Inc.

KEW Group Inc. provides multiple services to oncologists to assist in treatment decisions for cancer patients: genomic testing for patient tumor samples (KEW MDx) and providing genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways (KEW TPx). KEW MDx's CancerPlexSM test is the first of its diagnostic services designed to assist community oncologists in providing state-of-the-art genomic testing that previously has been available at large cancer treatment and academic centers. KEW is currently working with seven oncology practices in six different states to refine Therapeutic Pathways for seven types of cancer (breast, colorectal, lung, melanoma, lymphoma, thyroid and pancreatic). These seven practices all participate in a Center for Medicare and Medicaid Innovation Grant, which is developing and testing a Community Oncology Medical Home model, known as COME HOME. The grant is administered through Innovative Oncology Business Solutions, Inc., the organization that oversees and manages COME HOME. KEW's Treatment Pathways integrate newly emerging cancer genomic information that follows evidence standards essential to how and when to perform molecular tests, as well as inform care decisions. 

KEW Investor Contact:
Kathy Behrens Wilsey

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Consolidation, Patent Loses, Weak R&D Productivity Depress ITO Transactions in Life Sciences Segment: Everest Group Annual Report
2. Polaris Group Files New IND for ADI-PEG 20 in Breast Cancer
3. WIRB-Copernicus Group Leaders Speak at Global Clinical Research Summit in South Korea
4. Global Stem Cells Group, Inc. Announces Worldwide Alliance with EmCyte Corp. to Promote In-office Regenerative Medicine Solutions
5. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
6. Reimbursement Marketing Agency Element Marketing Group Inc. Opens New Office in Irvine, California
7. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
8. Bangkok Hospital Group Selects ClinicalKey to Enhance Medical Practice and Improve Patient Care
9. The Arrow Group of Animal Hospitals in Central Arizona Partners with Vet-Stem, Inc. to Bring Stem Cell Therapy to Their Patients
10. Dennis R. Hill, MD to Speak at the American Cancer Society Man-to-Man Support Group to Discuss HDR Brachytherapy for Prostate Cancer Treatment
11. RGF Environmental Group Acquires AFL Industries
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 ... new market research report "Oligonucleotide Synthesis Market by Product ... (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical ... published by MarketsandMarkets, the market is expected to reach ... in 2015, at a CAGR of 10.1% during the ...
(Date:11/24/2015)... November 24, 2015 --> ... research report released by Transparency Market Research, the global ... a CAGR of 17.5% during the period between 2014 ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends ... prenatal testing market to reach a valuation of US$2.38 ...
(Date:11/24/2015)... ... November 24, 2015 , ... In ... paramount. Insertion points for in-line sensors can represent a weak spot where leaking ... 781/784 series of retractable sensor housings , which are designed to tolerate extreme ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):